Flyrcado™ : A Breakthrough In Cardiac PET Imaging For Coronary Artery Disease
In a landmark advancement for nuclear cardiology, GE HealthCare has launched Flyrcado™ (flurpiridaz F 18), the first FDA-approved unit-dose positron emission tomography (PET) myocardial perfusion imaging (MPI) agent for detecting coronary artery disease (CAD). Approved in September 2024 and commercially available in select U.S. markets...
0 Kommentare 0 Geteilt 588 Ansichten 0 Bewertungen
Gesponsert
Gesponsert
Gesponsert
google-site-verification: google037b30823fc02426.html